The earnings call highlighted the successful commercial launch of KOSTAIVE in Japan and positive clinical trial results, indicating significant progress in Arcturus' pipeline. However, financial challenges such as a decrease in revenue and a reported net loss, along with delays in data for the OTC program, were noted. Overall, the sentiment is balanced with notable achievements and ongoing challenges.

Company Guidance

In the third quarter of 2024 earnings call, Arcturus Therapeutics provided several key metrics and guidance details. The company reported Q3 revenues of $41.7 million, a decrease from the previous year's $45.1 million, primarily due to a reduction in CSL revenue. However, the company received a $25 million commercial milestone following the launch of its COVID-19 vaccine, KOSTAIVE, in Japan. Arcturus reported a net loss of $6.9 million or $0.26 per diluted share for Q3 2024, compared to a net loss of $16.2 million or $0.61 per diluted share in Q3 2023. Operating expenses for the quarter were $52.4 million, down from $64.5 million in the previous year. The company anticipates that its cash runway, which stood at $294.1 million as of September 30, 2024, will extend into the first quarter of 2027. Looking ahead, Arcturus plans to file a BLA for KOSTAIVE in the U.S. in the first half of 2025, supported by positive Phase III results. Additionally, interim Phase II data for its therapeutic programs, ARCT-032 and ARCT-810, is expected in the first half of 2025.

Commercial Launch of KOSTAIVE in Japan

Arcturus launched KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine, in Japan, marking the first commercial product in the company's history. They received a $25 million commercial milestone from this launch.

Positive Phase III Results for ARCT-2303

ARCT-2303, a monovalent XBB variant of KOSTAIVE, met all primary and key secondary objectives in Phase III trials, demonstrating superior immune response against Omicron variants.

FDA Clearance for ARCT-032 IND in Cystic Fibrosis

Arcturus received FDA clearance for an IND application for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, enabling the initiation of a Phase II study.

Strong Financial Position

Arcturus reported cash, cash equivalents, and restricted cash of $294.1 million as of September 30, 2024, with a projected cash runway extending into Q1 2027.

---

Arcturus Therapeutics (ARCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 03, 2025	2024 (Q4)	-0.56 / -	-0.32	―	―	―
Nov 07, 2024	2024 (Q3)	-1.22 / -0.26	-0.61	57.38% (+0.35)
Aug 05, 2024	2024 (Q2)	-1.50 / -0.64	-1.98	67.68% (+1.34)
May 08, 2024	2024 (Q1)	-1.23 / -1.00	1.87	-153.48% (-2.87)
Mar 07, 2024	2023 (Q4)	-0.99 / -0.32	4.33	-107.39% (-4.65)	―
Nov 14, 2023	2023 (Q3)	-1.69 / -0.61	-1.33	54.14% (+0.72)	―
Aug 07, 2023	2023 (Q2)	-0.24 / -1.98	-0.82	-141.46% (-1.16)	―
May 09, 2023	2023 (Q1)	0.06 / 1.87	-1.94	196.39% (+3.81)	―
Mar 28, 2023	2022 (Q4)	-1.72 / 4.33	-1.47	394.56% (+5.80)	―
Nov 09, 2022	2022 (Q3)	-1.81 / -1.33	-2.05	35.12% (+0.72)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ARCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 07, 2024	$18.74	$19.62	+4.70%
Aug 05, 2024	$19.79	$19.83	+0.20%
May 08, 2024	$27.21	$26.79	-1.54%
Mar 07, 2024	$37.19	$36.86	-0.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---